stocks logo

TECX

Tectonic Therapeutic Inc
$
22.320
+0.04(0.180%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
23.000
Open
22.380
VWAP
22.53
Vol
155.42K
Mkt Cap
416.77M
Low
22.090
Amount
3.50M
EV/EBITDA(TTM)
--
Total Shares
18.67M
EV
111.28M
EV/OCF(TTM)
--
P/S(TTM)
--
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Show More
7 Analyst Rating
up Image
268.86% Upside
Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is 82.33 USD with a low forecast of 69.00 USD and a high forecast of 101.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image
268.86% Upside
Current: 22.320
sliders
Low
69.00
Averages
82.33
High
101.00
Truist
initiated
$64
2025-07-21
Reason
Truist initiated coverage of Tectonic Therapeutic with a Buy rating and $64 price target. Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction and Truist is cautiously optimistic that TX45 will be successful in its ongoing Phase 2 study, the analyst tells investors in a research note. Truist likes the current risk-reward.
Raymond James
Outperform
initiated
$76
2025-06-10
Reason
Raymond James resumed coverage of Tectonic Therapeutic with an Outperform rating and $76 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm contends that its lead asset, TX45 offers among the most compelling risk/reward propositions within a biotech landscape currently awash with suppressed valuations and favorable skew, Raymond James added. The firm notes that the ongoing Phase 2 targets a high unmet need indication which favorably aligns with relaxin's multi-modal mechanism of action.
LifeSci Capital
Outperform
initiated
$87
2025-06-05
Reason
LifeSci Capital initiated coverage of Tectonic Therapeutic with an Outperform rating and $87 price target.
Mizuho
Uy Ear
Outperform
maintain
$51 -> $85
2025-05-15
Reason
Mizuho
Uy Ear
Buy
Initiates
$51
2025-04-21
Reason
Wells Fargo
Tiago Fauth
Buy
Maintains
$112 → $101
2025-03-21
Reason
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Tectonic Therapeutic to $101 from $112 and keeps an Overweight rating on the shares. The firm thinks Tectonic Therapeutic is undervalued given noise around a competitor's discontinuation of their program in a different indication and some misconceptions around the relaxin mechanism. Wells believes this sets up one of the most attractive risk/rewards in its coverage.

Valuation Metrics

The current forward P/E ratio for Tectonic Therapeutic Inc (TECX.O) is -5.11, compared to its 5-year average forward P/E of -6.11. For a more detailed relative valuation and DCF analysis to assess Tectonic Therapeutic Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.11
Current PE
-5.11
Overvalued PE
-4.01
Undervalued PE
-8.21

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.42
Current EV/EBITDA
-1.38
Overvalued EV/EBITDA
0.40
Undervalued EV/EBITDA
-1.23

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+41.10%
-18.30M
Operating Profit
FY2025Q1
YoY :
+4.50%
-15.91M
Net Income after Tax
FY2025Q1
YoY :
-9.71%
-0.93
EPS - Diluted
FY2025Q1
YoY :
+41.32%
-13.11M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.6M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
11
51.1M
USD
Months
6-9
0
0.0
USD
Months
0-12
2
11.5M
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 215.5% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.6M
Volume
Months
6-9
2
517.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

TECX News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
08:21:36
Tectonic Therapeutic joins Russell 3000 Index
select
2025-01-30 (ET)
2025-01-30
05:37:10
Tectonic Therapeutic reports 'positive' data from Phase 1b trial for TX45
select
2025-01-28 (ET)
2025-01-28
13:49:45
Leerink says Eli Lilly news causes concern about Tectonic's TX45 success
select
Sign Up For More Events

News

4.5
06-30Newsfilter
Tectonic Therapeutic Joins Russell 3000® Index
4.0
06-11Benzinga
Raymond James Reinstates Outperform on Tectonic Therapeutic, Announces $76 Price Target
4.0
06-07NASDAQ.COM
LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation
Sign Up For More News

FAQ

arrow icon

What is Tectonic Therapeutic Inc (TECX) stock price today?

The current price of TECX is 22.32 USD — it has increased 0.18 % in the last trading day.

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s business?

arrow icon

What is the price predicton of TECX Stock?

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s revenue for the last quarter?

arrow icon

What is Tectonic Therapeutic Inc (TECX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Tectonic Therapeutic Inc (TECX)'s fundamentals?

arrow icon

How many employees does Tectonic Therapeutic Inc (TECX). have?

arrow icon

What is Tectonic Therapeutic Inc (TECX) market cap?